Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

기사 요약

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.